Crossmark

Testing the Feasibility of a Digital Point of Care Solution for the Trusted Near Real-Time Bidirectional Exchange of Novel and Informative Adverse Event Information

Crossref DOI link: https://doi.org/10.1007/s43441-024-00711-9

Published Online: 2024-11-17

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Powell, Greg

Kara, Vijay

Naranjo, Daniel

Kulkarni, Mangesh

Best-Sule, Kerri

Coster, Trinka

Bonafede, Machaon

Gangadhar, Shruti

Kallenbach, Lee

Bate, Andrew
Funding

Funding for this research was provided by:

GlaxoSmithKline
License Information

Text and Data Mining valid from 2024-11-17

Version of Record valid from 2024-11-17
More Information

Article History

Received: 22 May 2024

Accepted: 12 October 2024

First Online: 17 November 2024

Declarations

:

: Veradigm received fees from GSK related to this work. MB, SG, and LK are employees of Veradigm and hold Veradigm stock. GP, VK, DN, MK, KB and AB are employees of GSK. GP, VK, DN, KB and AB hold GSK stock or stock options. TC is an employee of Pharmacocybernetics and received fees from Veradigm.

Document is current

Any future updates will be listed below